Clinical Trials

EGFR Positive Non-small Cell Lung Cancer

NCT05611879 2023-12-29

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Carcinoma, Non-Small-Cell Lung

NCT06110663 2023-11-01

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

314 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03380468 2023-07-20

ECTOP-1004

Phase 2/3 Unknown

300 enrolled

Adenocarcinoma of Lung, Lung Neoplasms

NCT05527808 2023-06-08

A Single-arm Exploratory Study of Neoadjuvant Therapy

Phase NA Unknown

28 enrolled

Adenocarcinoma of Lung

NCT05810350 2023-04-13

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

228 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01656551 2023-03-24

MILES-4

232 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04396457 2023-03-23

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

50 enrolled

Lung Neoplasms

NCT04638582 2023-03-22

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

44 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05741021 2023-02-24

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05648071 2022-12-13

SPBPDC

Advanced Non-squamous Non-Small-Cell Lung Cancer

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02436733 2022-11-07

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Other solid neoplasmThoracic

64 enrolled

Mesothelioma, Malignant

NCT05574998 2022-10-12

FTANLCNDG

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05477615 2022-07-28

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05458726 2022-07-26

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04459611 2022-07-12

neoSCORE

Carcinoma, Non-Small-Cell Lung

NCT05448781 2022-07-07

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05430802 2022-06-24

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

Carcinoma, Non-Small-Cell Lung

NCT05394233 2022-05-27

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

20 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT05346952 2022-04-26

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

390 enrolled

Advanced Non-squamous Non-small Cell Lung Cancer

NCT01951469 2022-03-08

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

160 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Phase 2/3 Unknown

90 enrolled

NSCLC

NCT02743923 2021-12-21

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

203 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04989322 2021-12-08

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

46 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04405674 2021-11-22

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03830411 2021-11-08

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

76 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT03863483 2021-11-08

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

70 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT04943029 2021-09-02

NEOSUN

Carcinoma, Non-Small-Cell Lung

NCT04586465 2021-08-24

DYNAPET

23 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Unknown

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04982549 2021-08-06

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

35 enrolled

Unresectable Stage III NSCLC

NCT02448797 2021-07-20

EVIDENCE

320 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04768075 2021-02-24

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

700 enrolled

Nonsquamous Non-small Cell Lung Cancer

NCT04713761 2021-01-26

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

15 enrolled

Mesothelioma, Malignant

NCT04706949 2021-01-13

Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04500704 2020-08-05

ACROSS1

166 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04500717 2020-08-05

ACROSS2

460 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT04470076 2020-07-14

Neoafa

Carcinoma, Non-Small-Cell Lung

NCT03987867 2020-07-07

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04455594 2020-07-02

ANSWER

168 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02737774 2020-07-01

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Adenocarcinoma of Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

762 enrolled

PD-L1 Positive Non-small Cell Lung Cancer

NCT03790228 2020-04-15

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Phase 1 Unknown

43 enrolled

Non-squamous Cell Non-Small Cell Lung Cancer

NCT03706287 2020-04-06

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Phase 1/2 Unknown

62 enrolled